Download Manuel Serrano, obtiene el Premio Banco Sabadell

Manuel Serrano, honoured with the Banco Sabadell
Award in Biomedical Research
Manuel Serrano, Leader of the Tumour Suppression Group of the C.N.I.O.,
has been granted the Banco Sabadell Award in Biomedical Research on its first
edition. The price acknowledges Manuel Serrano career so far in anti-cancer
research. The Jury of experts, presided over by the reputed oncologist Josep
Baselga assessed Manuel Serrano as one of the scientists of higher scope and a
future reference within the molecular oncology field.
The sponsors of the Banco Sabadell Award in Biomedical Research envision this
reward, on their own account, as a recognition to quality in research, talent and
innovation capability in scientists under 45 years of age that have opted to pursue their
research projects in Spain rather than abroad.
The members of the Jury thought this was the case in Manuel Serrano (Madrid 1964),
Tumour Suppression Group Leader at the C.N.I.O., who was regarded as one of the most
promising young scientists in the fight against cancer at both the national and international
levels.
Manuel Serrano took his Ph.D. degree in Biochemistry and Molecular Biology on 1991 at
Centro de Biología Molecular “Severo Ochoa” (C.S.I.C.-U.A.M.) in Madrid and he carried
out his postdoctoral work at Cold Spring Laboratory in New York from 1992 to 1996. He
afterwards led his own research group at Centro Nacional de Biotecnología (C.S.I.C.) in
Madrid between 1997 and 2003. On that last year he took up the leadership of the
Tumour Suppression Group at the C.N.I.O.
The research endeavours of Manuel Serrano focus mainly on the study of our defences
against tumours, more precisely, how the genes that lend protection against cancer work.
Some 20 genes are known to take part on that process, the group lead by Serrano
analyses three of those genes, of which the best known one is the p53 gene, that is
inactive in one of every two tumours. The research of the Tumour Suppression Group
attempts to provide a starting point to enable the development of anti-cancer drugs
capable of a specific stimulation of our protection against cancer.
The prize-granting Jury was presided over by Josep Baselga, an oncologists of the greatest
international repute, member of the Board of Directors of the American Society of
Clinical Oncology and sitting Head and Co-ordinator of the Oncology, Clinical
Haematology and Radiotherapy Unit at Hospital Vall d’Hebron. The Jury was participated
by such relevant scientific personalities as Octavi Quintana, Health Research Director of
the European Commission; Jordi Camí, General Director General of Parc de Recerca
Biomèdica in Barcelona; Francisco Fernández Avilés, Director of the Sciences Institute at
Hospital Clínico in Valladolid; Ramón Gomis, Research Director of Hospital Clínic in
Barcelona; Isabel Illa Sendra, member of the Neurology Facility at Hospital de la Santa
Creu i Sant Pau in Barcelona, José López Barneo, member of the Biomedical Research
Laboratory at Hospital Virgen del Rocío in Sevilla; Carlos López-Otin, Professor of
Biochemistry and Molecular Biology at the University of Oviedo; and Alberto Muñoz
Terol, a member of Instituto de Investigaciones Biomédicas “Alberto Sols” (C.S.I.C.).
A total of 26 scientists, belonging to 21 scientific institutions from all over Spain, opted to
this first edition of Banco Sabadell Award in Biomedical Research. All candidates
enjoyed the backing of personalities affiliated to hospitals, universities or research centres.
Award to be presented on October 10
The award, endowed with 15.000 euros, will be handed to Manuel Serrano in Barcelona
on October 10. The gala will be presided by Marina Geli, Health Councillor of the
Catalonian Authority; Josep Oliu, the president of Bank of Sabadell, will be in attendance,
as well as the President and members of the Jury.